The invention relates to quinazoline derivatives substituted by aniline which are represented by the below formula (I), pharmaceutical acceptable salts and stereoisomer thereof, wherein these groups of R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, L and n have the meanings given in the specification. The invention also relates to preparation methods, pharmaceutical compositions, pharmaceutical preparation and the use for preparation of medicine of treating excessive hyperplasia and chronic obstructive pulmonary disease and uses for treating excessive hyperplasia and chronic obstructive pulmonary disease thereof. ##STR00001##

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.

Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.

Disclosed in the present invention is a triketone compound which has a structure shown in Formula (I). Also disclosed in the present invention is a method for preparing the triketone compound having a structure as shown by Formula (I), which comprise that under the rearrangement reaction conditions, the compound having a structure as shown by Formula (II) is contacted with a catalyst in the presence of a base and a solvent. Further disclosed in the present invention is the use of a triketone compound having a structure as shown by Formula (I) in preventing and controlling weeds. Said triketone compound having a structure as shown by formula (I) in the present invention has the effect of preventing and controlling weeds, in particular having an excellent effect on preventing and controlling broadleaved weeds and/or gramineae weeds.

Disclosed in the present invention is a triketone compound which has a structure shown in Formula (I). Also disclosed in the present invention is a method for preparing the triketone compound having a structure as shown by Formula (I), which comprise that under the rearrangement reaction conditions, the compound having a structure as shown by Formula (II) is contacted with a catalyst in the presence of a base and a solvent. Further disclosed in the present invention is the use of a triketone compound having a structure as shown by Formula (I) in preventing and controlling weeds. Said triketone compound having a structure as shown by formula (I) in the present invention has the effect of preventing and controlling weeds, in particular having an excellent effect on preventing and controlling broadleaved weeds and/or gramineae weeds.

The present invention provides a 2-aminoquinazolinone derivative. The present invention is a compound represented by formula (1)

##STR00001##

[wherein X.sup.1 represents CR or N, X.sup.2 represents CR.sup.2 or N, X.sup.3 represents CR.sup.3 or N, Y represents an optionally substituted C.sub.6-10 aryl or optionally substituted 6 to 10-membered heteroaryl, Z represents an optionally substituted C.sub.6-10 aryl, R.sup.A represents a hydrogen atom, halogen, cyano, optionally substituted C.sub.1-6 alkyl sulfonyl, optionally substituted C.sub.1-6 alkyl, or optionally substituted C.sub.1-6 alkoxy, and R.sup.1, R.sup.2, and R.sup.3 independently represent a hydrogen atom, halogen, optionally substituted C.sub.1-6 alkyl, or optionally substituted C.sub.1-6 alkoxy] or a pharmaceutically acceptable salt thereof.

The present invention provides a 2-aminoquinazolinone derivative. The present invention is a compound represented by formula (1)

##STR00001##

[wherein X.sup.1 represents CR or N, X.sup.2 represents CR.sup.2 or N, X.sup.3 represents CR.sup.3 or N, Y represents an optionally substituted C.sub.6-10 aryl or optionally substituted 6 to 10-membered heteroaryl, Z represents an optionally substituted C.sub.6-10 aryl, R.sup.A represents a hydrogen atom, halogen, cyano, optionally substituted C.sub.1-6 alkyl sulfonyl, optionally substituted C.sub.1-6 alkyl, or optionally substituted C.sub.1-6 alkoxy, and R.sup.1, R.sup.2, and R.sup.3 independently represent a hydrogen atom, halogen, optionally substituted C.sub.1-6 alkyl, or optionally substituted C.sub.1-6 alkoxy] or a pharmaceutically acceptable salt thereof.

The present invention provides a 2-aminoquinazolinone derivative. The present invention is a compound represented by formula (1) ##STR00001##
[wherein X.sup.1 represents CR or N, X.sup.2 represents CR.sup.2 or N, X.sup.3 represents CR.sup.3 or N, Y represents an optionally substituted C.sub.6-10 aryl or optionally substituted 6 to 10-membered heteroaryl, Z represents an optionally substituted C.sub.6-10 aryl, R.sup.A represents a hydrogen atom, halogen, cyano, optionally substituted C.sub.1-6 alkyl sulfonyl, optionally substituted C.sub.1-6 alkyl, or optionally substituted C.sub.1-6 alkoxy, and R.sup.1, R.sup.2, and R.sup.3 independently represent a hydrogen atom, halogen, optionally substituted C.sub.1-6 alkyl, or optionally substituted C.sub.1-6 alkoxy] or a pharmaceutically acceptable salt thereof.